SCHEMBL4769149

SCHEMBL4769149

CCN1CCN(c2nc(-c3ccc4c(c3)OCO4)cc3ccccc23)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
HSD17B10 Q99714 2/20 0.53
USP2 O75604 1/20 0.53
CYP2C19 P33261 1/20 0.53
CLK4 Q9HAZ1 1/20 0.53
ALOX15 P16050 1/20 0.47
ROCK2 O75116 1/20 0.45
ROCK1 Q13464 1/20 0.45
PKN2 Q16513 1/20 0.45
KDM4E B2RXH2 4/20 0.44
LMNA P02545 4/20 0.44
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4770123 0.99 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP3A4CYP2D6HSD17B10
SCHEMBL6292092 0.94 CYP1A2 (0.45) ALDH1A1CYP1A2CYP3A4CYP2D6HSD17B10
Hydrochloric Acid SCHEMBL4766366 0.93 CYP1A2 (0.44) ALDH1A1CYP1A2CYP3A4CYP2D6HSD17B10
SCHEMBL4763718 0.82 ROCK2 (0.47) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL4766412 0.81 ROCK2 (0.46) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL6292078 0.81 KMT2A (0.59) ALDH1A1CYP1A2CYP2D6CYP2C19ROCK2
SCHEMBL4764112 0.81 SMN1; SMN2 (0.47) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4773428 0.81 SMN1; SMN2 (0.47) ALDH1A1CYP1A2CYP2D6CYP2C19ROCK2
SCHEMBL4773872 0.81 SMN1; SMN2 (0.47) CYP1A2CYP2D6CYP2C19ROCK2ROCK1
Hydrochloric Acid SCHEMBL4769154 0.80 SMN1; SMN2 (0.46) CYP1A2CYP2D6CYP2C19ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US claimed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP claimed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ALDH1A1 2989/4885CYP1A2 2126/4885CYP3A4 1309/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ALDH1A1 1071/4885CYP1A2 1489/4885CYP3A4 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.